ClinicalTrials.gg
RecruitingNCT04998578Updated Dec 11, 2023

Comparison Of Aesthetic Techniques For Rejuvenation Of Genital Region: A Randomized Clinical Trial

An interventional study of Comparison of aesthetic techniques in Laxity; Skin, Skin Hyperpigmentation and Needlestick Puncture, sponsored by Centro de Atenção ao Assoalho Pélvico. Recruiting at 2 sites in Brazil. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-12-11.

Sponsored by Centro de Atenção ao Assoalho Pélvico · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Oct 2021; still recruiting 5 years 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

The microneedle is a minimally invasive technique, consists of the application of a roller surrounded by small and thin needles that pierce the skin and generate a mechanical stimulus with no ablative effect on the skin. The study aims to test the hypothesis that the technique of microneedle in the treatment of tissue flaccidity and hyperchromia of female external genitalia is safe and with a more effective result in clinical improvement through genital rejuvenation and unification of skin tone when compared to non-ablative radiofrequency technique.

Read the detailed description

Dissatisfaction with the genital image has been receiving more attention in recent years and is influenced by mediation and the methods of waxing modernity. In the face of this, the number of women in search for aesthetic female genital surgeries. Since the year 2015, the implementation of the Labiaplasty surgery had a growth of 45% worldwide. Brazil is a leader in the procedure, with a total of 23,155 procedures in the year 2016 (ISAPS DATA). However, the Most genital surgical cases are performed unnecessarily, without long-term term, according to a conflict of interest arising from financial gain, generating ethical complications The search for aesthetic non-invasive genital treatments, in its majority, is related to sagging big lips and genital hyperchromia. In the literature, the non-invasive therapeutic resource and with fewer adverse effects described for aesthetics of the genital region is the use of the radiofrequency apparatus ablative, considered to be a safe and effective technique for flaccidity of the cutaneous tissue. It is not described in the literature treatments used for genital hyperchromia, however, several formulations for clearings using Kojic acid and Niacinamide, already described as effective for other regions, are available for marketing primarily for genital year whitening.

Minimally invasive technique, consists of the application of a roller surrounded by small and thin needles that pierce the skin and generate a mechanical stimulus with no ablative effect on the skin.

02

Conditions studied

  • Laxity; Skin
  • Skin Hyperpigmentation
  • Needlestick Puncture

Browse trials for

Keywords

  • microneedling
  • laxity
  • Skin Hyperpigmentation
03

In context

Hyperpigmentation

127 studies on the registry are indexed under Hyperpigmentation; 28 are open to participants now.

This study's planned enrollment of 112 is above the median of 32 across 113 interventional studies indexed under Hyperpigmentation.

Browse Hyperpigmentation studies →

Lead sponsor

Centro de Atenção ao Assoalho Pélvico is the lead sponsor of 17 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18-65 years with skin flaccidity and genital hyperchromia

Exclusion criteria

Exclusion Criteria:

  • Patients who use cosmetics in the genital region
  • Use of anticoagulant medication
  • Use of pacemakers
  • Pregnancy
  • Dermatoses in the region to be treated and / or local inflammatory condition, without diagnosis of infection
  • Difficulty in understanding the proposed instruments
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
112 participants (estimated)

Study arms

  • Active comparator
    Microneedling- Group A

    Participants will only perform microneedling

    Device: Comparison of aesthetic techniques

  • Active comparator
    Microneedling and outpatient Cosmetics- Group B

    Microneedling associated with the use of outpatient cosmetics

    Device: Comparison of aesthetic techniques

  • Active comparator
    microneedling and home use cosmetics - Group C

    Microneedling associated with home use cosmetics

    Device: Comparison of aesthetic techniques

  • Active comparator
    Non-ablative radiofrequency - Group D

    Participants will perform only non-ablative radiofrequency

    Device: Comparison of aesthetic techniques

Interventions

  • DeviceComparison of aesthetic techniques

    Comparison of aesthetic techniques for rejuvenation and glazing of the genital region

06

What researchers measure

Primary outcomes

  1. External genital Laxity

    It will be evaluated by turgor, number of skinfolds, evidenced by self report, comparison of images taken before and after the procedure and satisfaction of the patient, verified in the Likert scale and Visual Analog Scale.

    Time frame: 1, 3, 6 and 12 months after treatment

  2. Genital Hyperchromia

    It will be evaluated the uniformity of the skin tone, evidenced by the self report, comparison of images taken before after the procedure and satisfaction of the participant, verified in the scale of Likert and Scale Visual Analog.

    Time frame: 1, 3, 6 and 12 months after treatment

Secondary outcomes

  1. Sexual function

    It will be evaluated through the questionnaire Sexual Quotient - Female Version (QS-F), Female Sexual Function Index (FSFI)

    Time frame: 1, 3, 6 and 12 months after treatment

  2. Female Genital Self-Image

    It will be evaluated through the Female Genital Self-Image Scale (FGSIS) \> 26

    Time frame: 1, 3, 6 and 12 months after treatment

  3. Melasma Quality of Life

    It will be evaluated through the Melasma Quality of Life Scale (MELASQoL).

    Time frame: 1, 3, 6 and 12 months after treatment

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Vieira-Baptista P, Marchitelli C, Haefner HK, Donders G, Perez-Lopez F. Deconstructing the genitourinary syndrome of menopause. Int Urogynecol J. 2017 May;28(5):675-679. doi: 10.1007/s00192-017-3295-6. Epub 2017 Mar 14. PubMed 28293790 ↗
  • Marnach ML, Torgerson RR. Vulvovaginal Issues in Mature Women. Mayo Clin Proc. 2017 Mar;92(3):449-454. doi: 10.1016/j.mayocp.2016.10.031. PubMed 28259230 ↗
  • Filippini M, Del Duca E, Negosanti F, Bonciani D, Negosanti L, Sannino M, Cannarozzo G, Nistico SP. Fractional CO2 Laser: From Skin Rejuvenation to Vulvo-Vaginal Reshaping. Photomed Laser Surg. 2017 Mar;35(3):171-175. doi: 10.1089/pho.2016.4173. Epub 2016 Dec 30. PubMed 28056209 ↗
  • Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause. 2014 Oct;21(10):1063-8. doi: 10.1097/GME.0000000000000329. PubMed 25160739 ↗
  • Lapii GA, Yakovleva AY, Neimark AI. Structural Reorganization of the Vaginal Mucosa in Stress Urinary Incontinence under Conditions of Er:YAG Laser Treatment. Bull Exp Biol Med. 2017 Feb;162(4):510-514. doi: 10.1007/s10517-017-3650-0. Epub 2017 Feb 27. PubMed 28243906 ↗
  • Ho D, Kraeva E, Wun T, Isseroff RR, Jagdeo J. A single-blind, dose escalation, phase I study of high-fluence light-emitting diode-red light (LED-RL) on human skin: study protocol for a randomized controlled trial. Trials. 2016 Aug 2;17:385. doi: 10.1186/s13063-016-1518-7. PubMed 27484782 ↗
  • Miyata S, Miyaji H, Kawasaki H, Yamamoto M, Nishida E, Takita H, Akasaka T, Ushijima N, Iwanaga T, Sugaya T. Antimicrobial photodynamic activity and cytocompatibility of Au25(Capt)18 clusters photoexcited by blue LED light irradiation. Int J Nanomedicine. 2017 Apr 4;12:2703-2716. doi: 10.2147/IJN.S131602. eCollection 2017. PubMed 28435253 ↗
  • Takada A, Matsushita K, Horioka S, Furuichi Y, Sumi Y. Bactericidal effects of 310 nm ultraviolet light-emitting diode irradiation on oral bacteria. BMC Oral Health. 2017 Jun 6;17(1):96. doi: 10.1186/s12903-017-0382-5. PubMed 28587675 ↗
  • Arunkalaivanan A, Kaur H, Onuma O. Laser therapy as a treatment modality for genitourinary syndrome of menopause: a critical appraisal of evidence. Int Urogynecol J. 2017 May;28(5):681-685. doi: 10.1007/s00192-017-3282-y. Epub 2017 Feb 2. PubMed 28154914 ↗
  • Nilsson K, Risberg B, Heimer G. The vaginal epithelium in the postmenopause--cytology, histology and pH as methods of assessment. Maturitas. 1995 Jan;21(1):51-6. doi: 10.1016/0378-5122(94)00863-3. PubMed 7731384 ↗
  • Flores SA, Hall CA. Atrophic Vaginitis. 2022 Oct 31. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK564341/ PubMed 33232011 ↗
  • Herbenick D, Reece M. Development and validation of the female genital self-image scale. J Sex Med. 2010 May;7(5):1822-30. doi: 10.1111/j.1743-6109.2010.01728.x. Epub 2010 Mar 3. PubMed 20233278 ↗
  • Cain JM, Iglesia CB, Dickens B, Montgomery O. Body enhancement through female genital cosmetic surgery creates ethical and rights dilemmas. Int J Gynaecol Obstet. 2013 Aug;122(2):169-72. doi: 10.1016/j.ijgo.2013.03.020. Epub 2013 Jun 2. PubMed 23735570 ↗
  • McPencow AM, Guess MK. Giving female genital cosmetic surgery a facelift. Maturitas. 2012 Apr;71(4):313-4. doi: 10.1016/j.maturitas.2012.01.012. Epub 2012 Feb 14. No abstract available. PubMed 22341089 ↗
  • Doddaballapur S. Microneedling with dermaroller. J Cutan Aesthet Surg. 2009 Jul;2(2):110-1. doi: 10.4103/0974-2077.58529. PubMed 20808602 ↗
  • Ramaut L, Hoeksema H, Pirayesh A, Stillaert F, Monstrey S. Microneedling: Where do we stand now? A systematic review of the literature. J Plast Reconstr Aesthet Surg. 2018 Jan;71(1):1-14. doi: 10.1016/j.bjps.2017.06.006. Epub 2017 Jun 17. PubMed 28690124 ↗
  • Fabbrocini G, De Vita V, Fardella N, Pastore F, Annunziata MC, Mauriello MC, Monfrecola A, Cameli N. Skin needling to enhance depigmenting serum penetration in the treatment of melasma. Plast Surg Int. 2011;2011:158241. doi: 10.1155/2011/158241. Epub 2011 Apr 7. PubMed 22567235 ↗
  • Goodman MP. Female genital cosmetic and plastic surgery: a review. J Sex Med. 2011 Jun;8(6):1813-25. doi: 10.1111/j.1743-6109.2011.02254.x. Epub 2011 Apr 14. PubMed 21492397 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Oct 2024, 36 months after the start.

Of 37 non-industry interventional studies with no phase under Hyperpigmentation, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's planned 36 months is above that.

Counting every sponsor, half of 64 studies reached it within 7 months; a quarter within 3 and three quarters within 25.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2019
First posted
Aug 10, 2021
StartActual
Oct 1, 2021
Primary completionEst.
Oct 1, 2024
CompletionEst.
Oct 1, 2024
Last update
Dec 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04998578
Lead sponsor
Centro de Atenção ao Assoalho Pélvico
Responsible party
Sponsor
First posted
Aug 10, 2021
Start date
Oct 1, 2021
Primary completion
Oct 1, 2024 (estimated)
Completion
Oct 1, 2024 (estimated)
Last update
Dec 11, 2023

Study contacts

Patrícia Lordelo
Contact
pvslordelo@hotmail.com
(71) 8859-2400/3330-1640

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion